Company intelligence / Profile preview
Deverra Therapeutics
Seattle, Washington, United Statesdeverratx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Dilanubicel, the company's lead product, has completed a global phase 2 randomized controlled trial in patients with newly diagnosed AML. Data demonstrated a statistically significant increase in remission rates in patients who received dilanubicel as an adjuvant to standard of care chemotherapy compared to standard of care chemotherapy alone[1].
- Therapeutic areas
- OncologyHematologyImmunologyInfectious Diseases
- Modalities
- Cell therapyAllogeneic cell therapyNK cell therapyCAR-NK cell therapyStem cell therapyMyeloid cell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Coeptis Therapeutics (DVX201 has been licensed to Coeptis Therapeutics)[1]
Beyond the preview
Go deeper on Deverra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deverra Therapeutics.